Podcast Episodes
Back to Search369: Trump, Chinese biotech, and an industry career reshaped by illness
Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week, he penned a poignant personal essay explaining how some medi…
Published on 12 hours ago
368: New stakes in the vaccine dispute and a boost for biotech
Labor Day is in the rearview mirror, and that means Adam, Elaine, and Allison are all back to work. They take the pulse of the biotech market and discuss forthcoming data readouts at two sleep and lu…
Published on 1 week ago
367: The ouster of CDC's director, biotech venture firm rankings
We bring on Washington correspondent Chelsea Cirruzzo to explain the ouster of CDC Cirector Susan Monarez and the resignations of other top officials.
We also chat about STAT's annual VC rankings rep…
Published on 2 weeks ago
366: Viking’s obesity flop, ‘pharma to table’ drug sales
On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Ther…
Published on 3 weeks ago
365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended
We discuss the sudden return of Prasad and the mixed prospects for mRNA. Then, we invite STAT fellow Marissa Russo on to discuss the alternatives to animal testing, and why they’re the subject of hot…
Published on 4 weeks ago
364: Closing a zombie biotech, and Lilly's disappointing obesity readout
We bring on Natalie Holles, who was the CEO of Third Harmonic Bio, which recently decided to dissolve and return cash to shareholders. She walks us through why the company has decided to do this and…
Published on 1 month ago
363: What Vinay Prasad’s ouster means for biotech and the FDA
This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s biologics division. This surprising development cam…
Published on 1 month, 1 week ago
362: A mother’s perspective on Sarepta’s gene therapy halt
We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food an…
Published on 1 month, 2 weeks ago
361: Inside an FDA drug rejection, and layoffs at Sarepta
Just how many employees is Sarepta Therapeutics laying off? And why did the Food and Drug Administration reject Ultragenyx’s rare disease drug over manufacturing qualms?
Ultragenyx CEO Emil Kakkis j…
Published on 1 month, 3 weeks ago
360: NIH grant cuts, FDA transparency questions and biotech M&A
On this week’s episode of the Readout LOUD: A closer look at the NIH’s grant-cutting legal playbook, a not-so-transparent transparency push by the FDA commissioner, and another big biotech acquisitio…
Published on 2 months ago